FDA Grants Dasatinib Priority Review for Children With Ph+ Chronic Phase CML

July 10, 2017 – The FDA has accepted a supplemental new drug application (sNDA) for dasatinib for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML). The agency also granted priority review for a powder for oral suspension (PFOS) formulation of dasatinib, according to Bristol … (leggi tutto)